Last updated on May 2020

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors


Brief description of study

The purpose of this study is to evaluate MEDI5752 in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.

Detailed Study Description

This is a phase 1, first-time-in-human, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety and tolerability, and efficacy, pharmacokinetics and Immunogenicity of MEDI5752 in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.

Clinical Study Identifier: NCT03530397

Find a site near you

Start Over

Research Site

Heidelberg, Australia
  Connect »

Research Site

Melbourne, Australia
  Connect »

Research Site

Randwick, Australia
  Connect »

Research Site

Incheon, Korea, Republic of
  Connect »

Research Site

Seoul, Korea, Republic of
  Connect »

Research Site

Barcelona, Spain
  Connect »

Research Site

Majadahonda, Spain
  Connect »

Research Site

Taichung, Taiwan
  Connect »

Research Site

Cheongju-si, Korea, Republic of
  Connect »

Research Site

Chapel Hill, NC United States
  Connect »

Research Site

Chattanooga, TN United States
  Connect »

Research Site

Nashville, TN United States
  Connect »

Research Site

Villejuif Cedex, France
  Connect »

Research Site

Lisboa, Portugal
  Connect »

Research Site

New York, NY United States
  Connect »

Research Site

Houston, TX United States
  Connect »

Research Site

Amsterdam, Netherlands
  Connect »